Tag: Roche

Roche Q1 Sales Rose 9%

Swiss drug major Roche reported that its group sales for the first-quarter rose 9 percent to 14.83 billion Swiss francs from last year's 13.58 billion francs, while it was up 8 percent at constant exc...

Roche and Novartis are Among the Biggest Spenders on R&D in 2018

Over the past decade Roche and Novartis consistently spent more on R&D than other big pharma groups, evaluate.com reports. Abbvie and Astrazeneca have added to their budgets. The world’s 12 big...

FDA Approved Use of Tecentriq with Chemotherapy

Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) tr...

European Approval for Roche’s Treatment for Rare Disease

Roche today announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterised by pro...

EC Approved Roche’s Hemlibra

First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison. Roche today announced that the European Commission has ap...

Xencor and Genentech to Develop Novel Therapeutics

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced ...

Accelerated Approval for Roche Breast Cancer Treatment

Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® ) for the treatment of adults with unres...

EC Approval for Roche’s Treatment of NSCLC

roche
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin...

Fifth BTD for AbbVie and Genentech Drug

AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted a fifth Breakthrough Therapy Designation (BTD) to venetoclax, for use in c...

Genentech Announced FDA Approval for Breast Cancer Treatment

Genentech, a member of the Roche Group, announced the U.S. Food and Drug Administration (FDA) has approved Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) inj...

Roche Fully Acquires Spark Therapeutics

Roche and Spark Therapeutics, Inc. today announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-...

Roche’s R/R DLBCL Drug Got Priority Review

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with ...

Priority Review for Personilized Med of Genentech

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib f...

NICE Recommends Roche’s Breast Cancer Drug for Post-Surgery

NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes. This positiv...

Roche Takes Part in WFH Humanitarian Aid Program

Roche has announced that it has joined the World Federation of Hemophilia (WFH) Humanitarian Aid Program, a landmark initiative leading the effort to change the lack of access to care and treatment fo...

Roche Plans to Expand Use of its Breast Cancer Drug

Roche has submitted a supplemental biologics license application in the US seeking to expand the use of Kadcyla (trastuzumab emtansine) to include the adjuvant treatment of people with HER2-positive e...